Gilead Sciences, Inc. (GILD) Shares Sold by RiverPoint Capital Management LLC

RiverPoint Capital Management LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,345 shares of the biopharmaceutical company’s stock after selling 95 shares during the period. RiverPoint Capital Management LLC’s holdings in Gilead Sciences were worth $237,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Webster Bank N. A. raised its position in shares of Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the last quarter. American Beacon Advisors Inc. acquired a new position in shares of Gilead Sciences during the 1st quarter worth about $143,000. Finally, Truepoint Inc. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth about $204,000. Hedge funds and other institutional investors own 73.88% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/2982179/gilead-sciences-inc-gild-shares-sold-by-riverpoint-capital-management-llc.html.

Gilead Sciences, Inc. (GILD) opened at 80.10 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The firm has a 50-day moving average of $82.46 and a 200 day moving average of $72.93. The stock has a market cap of $104.60 billion, a PE ratio of 8.70 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.08 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post $8.77 EPS for the current year.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $242,749,648.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock valued at $36,338,919 over the last 90 days. Insiders own 1.30% of the company’s stock.

Several research analysts recently weighed in on GILD shares. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Jefferies Group LLC restated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 4th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a research report on Monday, July 17th. Redburn Partners started coverage on shares of Gilead Sciences in a research report on Wednesday, July 26th. They set a “buy” rating for the company. Finally, Deutsche Bank AG restated a “buy” rating and set a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $85.64.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.